U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

The Food and Drug Administration on Friday approved AstraZeneca (AZN) PLC’s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I wonder if this drug might be adapted to be used as a pre-emptive for those who have the BRCA gene but have not yet developed breast cancer, stopping it in it’s tracks before it ever shows up! That would certainly be cause for celebration!!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy